Climb Bio $CLYM

Health Care · NASDAQ

$9.19
-0.09 (-0.97%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 6, 2026, the first target we tracked for CLYM.

Climb Bio (CLYM) is trading down at $9.19 (-0.97%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on CLYM

Current price targets from 2 firms average $26, ranging from $25 to $27 — 183% above the current $9.19. Each is tracked to its date and scored the same way a member's call is.

2 targets, newest first. Open a row for its source and scoring.

DateNov 6, 2026 FirmWedbush RatingOutperform · raises Targetat $10.1 · $27 +168% Horizonby Nov 2027 StatusOpen

Entry price $10.1, the close nearest Nov 6, 2026, when the target was reported; the target is +168% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 6, 2027.

Source Wedbush keeps Climb Bio on Best Ideas List, raises price target Investing.com · Nov 6, 2026 · opens the publisher's site
Wedbush raised its price target to $27 from $25
DateNov 6, 2026 FirmOppenheimer RatingOutperform · reiterates Targetat $10.3 · $25 +143% Horizonby Nov 2027 StatusOpen

Entry price $10.3, the close nearest Nov 6, 2026, when the target was reported; the target is +143% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 6, 2027.

Source Oppenheimer reiterates Climb Bio stock rating on SLE data Investing.com · Nov 6, 2026 · opens the publisher's site
Oppenheimer reiterated an Outperform rating and $25.00 price target on Climb Bio (NASDAQ:CLYM) shares.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Climb Bio net income history (FY2020–FY2025)

Net income
$0−$36.9M−$73.9MFY2020 net income: −$20.7M'20FY2021 net income: −$47.5M'21FY2022 net income: −$45.2M'22FY2023 net income: −$35.1M'23FY2024 net income: −$73.9M'24FY2025 net income: −$59.9M'25
Climb Bio annual financial statements
FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Operating income−$20.9M−$35.7M−$45.1M−$40.3M−$82.0M−$67.9M
Net income−$20.7M−$47.5M−$45.2M−$35.1M−$73.9M−$59.9M
EPS (diluted)−$4.66−$2.83−$1.72−$1.30−$1.53−$0.88
Balance sheet
Cash and equivalents$20.5M$46.9M$43.6M$93.1M$87.2M$35.7M
Total assets$24.6M$173.2M$135.0M$110.5M$217.2M$167.7M
Total liabilities$3.06M$6.04M$6.28M$2.87M$5.31M$7.27M
Shareholders' equity−$25.0M$167.2M$128.7M$107.6M$211.9M$160.5M
Cash flow
Operating cash flow−$14.1M−$36.1M−$37.4M−$20.6M−$15.6M−$54.4M
Capital expenditure———$0$0$186.0K
Free cash flow———−$20.6M−$15.6M−$54.5M

From Climb Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Climb Bio in the news

Nov 18, 2026 Investing.com Climb Bio stock price target maintained at $30 by B.Riley on execution focus
Nov 9, 2026 Investing.com Climb Bio at Guggenheim healthcare conference: pipeline nears pivotal tests
Nov 6, 2026 Investing.com Wedbush keeps Climb Bio on Best Ideas List, raises price target Target
Nov 6, 2026 Investing.com Oppenheimer reiterates Climb Bio stock rating on SLE data Target
Oct 27, 2026 Investing.com Piper Sandler reiterates Climb Bio stock rating after ASN data
Show 1 older story
Sep 16, 2026 Investing.com Climb Bio at Morgan Stanley conference: two lead drugs, long runway

About Climb Bio

Headquarters
Wellesley Hills, Massachusetts From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →